Track market-moving stories before they get noisy

MarketBeat Week in Review – 02/03 - 02/07Teva Pharmaceutical Industries NYSE: TEVA said its internally developed anti-IL-15 antibody produced encouraging 24-week efficacy results in a phase 1b proof-of-concept study for vitiligo, as the company highlighted the program as part of its broader shift toward a biopharma-focused growth strategy.

During a conference call, President and CEO Richard Francis called the data “a milestone” in Teva’s “Pivot to Growth” plan and said 2026 is expected to include eight key events for the company, up from a prior expectation of seven following the addition of an ecopipam NDA filing.

Get TEVA alerts:

Teva Pharma: Why This Generic Drug Giant Is a Smart Buy NowFrancis said Teva’s pipeline includes several programs that the company believes could each become $1 billion products in their respective indications, including anti-IL-15, duvakitug, emricasan, DARI, ecopipam and olanzapine-related programs. He said Teva expects its innovative portfolio to generate $3.5 billion of revenue in 2026.

Vitiligo Study Shows Facial and Total Body Responses Eric A. Hughes, Teva’s EVP of Global R&D and Chief Medical Officer, said vitiligo is an autoimmune disease in which an immune reaction destroys melanocytes, leading to loss of pigmentation. He said the disease affects about 0.5% to 2% of the global population and carries a psychological burden, including anxiety, depression and social isolation.

2 Generic Drug Stocks Ready to Surge in 2025Hughes said the only FDA-approved treatment currently available is a topical therapy for patients with less than 10% body surface area involvement, leaving a need for systemic options that can treat the whole body.

The phase 1b study evaluated Teva’s anti-IL-15 antibody in approximately 38 patients. Participants received one subcutaneous dose at day zero and another at week 12, with efficacy measured at 24 weeks. Hughes said 66% of patients in the study had skin involvement greater than 10% of their body surface area.

Teva reported the following 24-week results after two doses:

42% of patients achieved F-VASI50, representing at least a 50% improvement in facial vitiligo. 21% of patients achieved F-VASI75, representing at least a 75% improvement in facial vitiligo. 7% of patients achieved T-VASI50, representing at least a 50% improvement in total body vitiligo. 75% of patients reported improvement in facial skin using the facial Patient Global Impression of Change score, with half of those reporting “much” to “very much” improvement. 55% of patients reported improvement in total skin using the total Patient Global Impression of Change score. Hughes said the patient-reported outcomes were particularly meaningful because patients monitor their skin daily and may be strongly affected by changes in appearance.

Company Highlights Quarterly Dosing Potential Hughes said Teva believes its anti-IL-15 antibody is differentiated by its potency, long half-life and target engagement. He described the molecule as “Teva-born” and said it was created by the same internal team that developed duvakitug.

According to Hughes, the antibody has a half-life of about 38 days. He said the company observed rapid suppression of free IL-15 levels in serum within one or two days, and at the top dose, suppression below the limit of quantitation extended to about 80 to 90 days. Based on those data, Hughes said dosing once per quarter is a “strong possibility.”

Hughes said the drug has been “very well tolerated” to date, with no safety signals seen so far. In response to an analyst question, he said Teva has followed patients from earlier studies for extended periods, including out to about 400 days in some phase 1 work, and has not seen adverse events associated with IL-15 rebound as levels return to baseline.

Teva Compares Data With Oral JAK Programs Hughes compared the phase 1b results with published data from upadacitinib, an oral JAK therapy that he said recently received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use.

He said Teva’s F-VASI50 result of 42% compared with 38% and 39% in the upadacitinib data he referenced. Teva’s F-VASI75 result of 21% compared with 19% and 14%, while its T-VASI50 result of 7% compared with 6% and 11%.

Hughes said Teva views the comparison as encouraging, particularly because its product is being developed as a subcutaneous injection given once every quarter. He contrasted that with daily oral JAK therapy, which he said carries a black box warning.

Phase 2 Plans and Additional Indications Teva said it has already met with the FDA and is incorporating the agency’s feedback into a phase 2 study expected to begin this year. Hughes said the company plans dose-ranging work in phase 2b and is discussing a seamless study design that could allow the program to move efficiently toward phase 3.

Hughes said Teva expects facial VASI and total VASI endpoints to be used in later-stage development, with baseline criteria likely to include greater than 0.5 on facial VASI and greater than five on total VASI. He also said Teva will continue monitoring phase 1b subjects out to 80 weeks.

Teva also emphasized potential applications for anti-IL-15 beyond vitiligo. Hughes said IL-15 may be relevant in alopecia areata, celiac disease, eosinophilic esophagitis and atopic dermatitis. The company expects proof-of-concept data from a phase 2a celiac disease study in the second half of the year.

That celiac study, Hughes said, includes about 50 patients in a placebo-controlled gluten challenge design. Patients receive either active treatment or placebo, then undergo a gluten diet challenge, with biopsies used to evaluate effects on gut histology. Hughes said the crypt depth-to-villus height ratio will be the most important readout.

Francis closed the call by saying the anti-IL-15 vitiligo data represent the second of eight expected milestones for Teva this year, with additional pipeline updates anticipated in the coming months.

About Teva Pharmaceutical Industries NYSE: TEVATeva Pharmaceutical Industries Ltd. NYSE: TEVA is an Israeli multinational pharmaceutical company and one of the world's largest manufacturers of generic medicines. The company's core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva's product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Teva Pharmaceutical Industries Right Now?Before you consider Teva Pharmaceutical Industries, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Teva Pharmaceutical Industries wasn't on the list.

While Teva Pharmaceutical Industries currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

NDA submission supported by positive Phase 3 data recently published in JAMA Neurology.Ecopipam is a first-in-class selective dopamine D1 receptor antagonist with a novel mechanism of action and has received FDA Orphan Drug and Fast Track designationsEcopipam could be the first FDA-approved treatment option for pediatric Tourette syndrome in more than a decade, if approved.
TEL AVIV, Israel, June 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ecopipam, a first-in-class investigational therapy for the treatment of pediatric Tourette syndrome.

“The NDA submission for ecopipam is a significant milestone for a potential first-in-class treatment option in pediatric Tourette syndrome,” said Eric Hughes, M.D., Ph.D., Executive Vice President, Global R&D and Chief Medical Officer of Teva. “This reflects the momentum in our innovative pipeline through our recent acquisition of this important asset, and advances our Pivot to Growth strategy and commitment to bringing differentiated medicines for patients.”

The NDA submission is supported by positive Phase 3 data recently published in JAMA Neurology, which showed that ecopipam significantly delayed time to relapse compared with placebo in pediatric patients with Tourette syndrome who had achieved a clinical response during the open-label treatment period. In the study, ecopipam demonstrated a statistically significant benefit on the primary efficacy endpoint in pediatric patients (p = 0.008) and was generally well tolerated, with the most common adverse events related to ecopipam therapy including somnolence, insomnia, anxiety, fatigue and headache.

About Tourette Syndrome

Tourette syndrome is a chronic neuro-developmental disorder character by involuntary motor and vocal tics beginning in childhood, often between 5 and 10 years of age. For people living with Tourette syndrome, symptoms can be frequent, visible, and disruptive, affecting everyday life. Despite the current treatment options available, many patients continue to experience inadequate treatment control or treatment-limiting side effects, underscoring the need for additional options.

About ecopipam

Ecopipam is a first-in-class investigational therapy designed to block dopamine signaling at the D1 receptor. D1 receptor hypersensitivity may contribute to repetitive and compulsive behaviors associated with Tourette syndrome.

Ecopipam has received Orphan Drug and Fast Track designations from the FDA for the treatment of pediatric patients with Tourette syndrome. Orphan Drug designation is reserved for patient populations of 200,000 or fewer.

Results from the Phase 3 study in Tourette syndrome were recently published in JAMA Neurology. The primary efficacy endpoint in the study was time to relapse (based on YGTSS-TTS scale) for pediatric patients who were stable and responding to ecopipam. The study showed statistical significance between ecopipam and placebo for the primary efficacy endpoint in pediatric patients (p = 0.008). Ecopipam was generally well-tolerated in the study and the most common adverse events related to ecopipam therapy were somnolence (n = 24 [11.1%]), anxiety (n = 21 [9.7%]), headache (n = 21 [9.7%]), insomnia (n = 19 [8.8%]), tic (n = 17 [7.9%]), and fatigue (n = 14 [6.5%]). 

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.

Teva Media Inquiries: [email protected] Investor Relations Inquiries: [email protected] Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause Teva’s future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements.

All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. In some cases, you can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “developing,” “target,” “may,” “expand,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future performance. Important factors that could cause or contribute to such differences include risks and uncertainties relating to: our ability to successfully develop, obtain regulatory approval for and commercialize ecopipam; our ability to successfully compete in the marketplace including our ability to develop and commercialize ecopipam and additional pharmaceutical products; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, and to execute on our organizational transformation and to achieve expected cost savings; our significant indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments; and other factors discussed in this press release, in our Quarterly Report on Form 10-Q for the first quarter of 2026 and in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the sections captioned “Risk Factors” and “Cautionary Note Regarding Forward Looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.